Persistence of Immune Response After Vaccination With MCC

Novartis

Status and phase: Completed; Phase 4

Conditions: Prevention of Meningococcal Infection

Treatments: Procedure: BLOOD DRAW

Study type: Interventional

Funder types: Industry

Identifiers

NCT00310687

M14P2E1

Impact N° 919

Details and patient eligibility

About

Persistence of Immune response after vaccination with MCC

Sex: All

Ages: 11 to 20 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy adolescents vaccinated with Meningococcal C Conjugate vaccine

Exclusion criteria

• ascertained or suspected disease caused by N. meningitidis
• household contact with individuals with proven N. meningitidis serogroup C infection
• significant acute or chronic infections
• any other serious disease

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)